Bio-Path completed the fifth cohort and has treated two patients in the sixth cohort of the Phase I clinical trial evaluating Liposomal Grb-2 in blood cancers. The drug’s safety profile continues to be favorable with no treatment-related serious adverse events reported and data suggests possible anti-leukemia activity. The clinical trial is being conducted at the MD Anderson Cancer Center. The Company anticipates completing enrollment of the sixth cohort in the first quarter of 2014.
In addition, Bio-Path announced its intent to conduct three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy in three different leukemia disease types: AML, CML and MDS. The Company anticipates starting this phase of development in the first half of 2014.
BIO-PATH CODE OF ETHICS AND BUSINESS CONDUCT (pdf)